Vycor Medical (OTC:VYCO) announced that its wholly-0wned subsidiary NovaVision entered into a licensing agreement with HelferApp GmbH.
The exclusive licensing agreement gives HelferApp the exclusive rights for NovaVision’s diagnostic products and therapies provided directly to patients and medical professionals in Germany, Austria and Switzerland, according to a news release.
Vycor previously said in May that it planned to close NovaVision’s German office and evaluate a transition to a license model for the subsidiary in Europe. NovaVision will look to partner with regional companies to leverage its clinically supported vision therapies, as well.
HelferApp plans to drive the adoption of NovaVision’s NeuroEyeCoach saccadic training program, which recently demonstrated effectiveness in assisting patients who have a visual field deficit with their visual search tasks, according to the release.
Existing NovaVision pat…